×
About 328 results

ALLMedicine™ Acquired Hemophilia A Center

Research & Reviews  110 results

Successful management of acquired hemophilia A onset during pregnancy: A case report.
https://doi.org/10.1111/jog.14938
The Journal of Obstetrics and Gynaecology Research; Nishi A, Muramatsu A et. al.

Jul 16th, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII. Pregnancy could be associated with AHA in younger women. Because of its rarity, the optimal management for pregnancy-related AHA...

Acquired hemophilia A associated with Epstein-Barr-virus-associated T/natural killer-ce...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078394
Medicine Yamamoto M, Shindo M et. al.

Apr 22nd, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Hematological malignancies, especially lymphoid malignancies, are known to be underlying causes of AHA; however, thus far, there is no re...

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 4th, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concent...
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.

Mar 1st, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literatur...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899955
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.

Feb 18th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  4 results

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
https://clinicaltrials.gov/ct2/show/NCT03384277

Dec 12th, 2019 - This is a prospective randomized multi-center controlled pilot trial comparing the regimen of steroid with rituximab and steroid with cyclophosphamide to eradicate anti-factor VIII antibodies in Chinese patients with acquired hemophilia A. Patient...

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT03700229

Nov 23rd, 2018 - This is a prospective, single-arm, open-label clinical trial to evaluate the efficacy and safety the regimen of Bortezomib with rituximab as first-line treatment to eradicate anti-factor VIII antibodies in newly diagnosed acquired hemophilia A. Al...

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT01178294

Oct 23rd, 2017 - This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT00306670

Feb 10th, 2017 - This is a prospective Phase II randomized multi-institutional controlled pilot trial comparing the regimen of single agent rituximab with 6 weeks cytotoxic therapy with oral cyclophosphamide to eradicate or suppress autoimmune anti-factor VIII ant...

see more →

News  11 results

An unusual cause of bruising
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

CardioBreak: Watchman Registry for CMS $$, U.K. Says No to PCSK9 Drug
https://www.medpagetoday.com/cardiology/prevention/54840

Nov 23rd, 2015 - Trends-in-Medicine (access restricted) dug up details on the proposed CMS coverage restrictions for the Watchman left atrial appendage (LAA) closure device, which revealed that: The agency is likely to clarify its requirement that patients not be ...

EC approves drug for acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/187468/thrombosis/ec-approves-drug-acquired-hemophilia
HT Staff

Nov 15th, 2015 - Vial of Obizur Photo courtesy of Baxter International Inc. The European Commission (EC) has approved a recombinant porcine factor VIII (FVIII) product, Obizur, to treat bleeding episodes in adults with acquired hemophilia A caused by autoantibodie.

see more →